It is known that FGFR3 alterations lead to oncogenic signaling through the MAPK and PI3K pathways and that these alterations are particularly sensitive to FGFR inhibitors, leading to the approval of erdafitinib for patients with advanced bladder cancer [38]. Here, FGFR3 is linked to urinary bladder cancer.